The Endocrine News Podcast, a free service of the Endocrine Society, features interviews with experts addressing the latest research and trends in the field of endocrinology. Let us know what you’d like to hear about in a future episode at podcast@endocrine.org.

We all know that a sedentary lifestyle is not healthy for anyone, but just how strongly is physical activity connected to lipid levels in childhood? Host Aaron Lohr talks with Andrew Agbaje, MD, PhD, a physician and pediatric clinical epidemiologist at the University of Eastern Finland. He has authored a study recently published in The Journal of Clinical Endocrinology & Metabolism titled, “Associations of Sedentary Time and Physical Activity From Childhood With Lipids: A 13-Year Mediation and Temporal Study.” Show notes are available at https://www.endocrine.org/podcast/enp83-sedentary-time-and-physical-activity-effects-on-childhood-lipid-levels — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we learn about endocrine-disrupting chemicals known as perfluoroalkyl and polyfluoroalkyl substances (PFAS), which break down so slowly that they have been called “forever chemicals.” Where can PFAS be found? What exactly is their effect on human health? What are manufacturers doing to limit exposure, and is it enough? Host Aaron Lohr talks with Benson T. Akingbemi, PhD, professor of anatomy and developmental biology at Auburn University. Dr. Akingbemi and colleagues recently published an article on PFAS in the journal Endocrinology titled, “Legacy and Emerging Perfluoroalkyl and Polyfluoroalkyl Substances Regulate Steroidogenesis in the Male Gonad.” Show notes are available at https://www.endocrine.org/podcast/enp82-pfas — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

According to the National Institutes of Health, more than two in five adults have obesity in the United States, and nearly one in three is overweight. To equip health care practitioners with the resources they need to treat patients with obesity, the Endocrine Society recently held its innaugual obesity fellows program, an exclusive, application-based, educational activity for current fellows. The program covered a wealth of information, and host Aaron Lohr talks with Amy Rothberg, MD, DABOM, program chair and a clinical professor of internal medicine at the University of Michigan’s School of Public Health. If you weren’t able to attend the fellows program, we have a free series of on-demand lectures available online, and those are accredited. With thanks to Lilly USA LLC and Novo Nordisk for making both the obesity fellows program and this podcast episode possible through an unrestricted, educational grant. Show notes, including a link to the Endocrine Society Learning Center for earning ABIM points and AMA PRA Category 1 credits, are available at https://www.endocrine.org/podcast/enp81-obesity-fellows-program — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We all know that sleep is important, but sometimes we just don’t get enough. We also know the normal side effects from lack of sleep, but are there other, metabolic, and neuronendocrine effects from short sleep that we don’t know about. Host Aaron Lohr talks about this with Iris CM Pelsma, an academic researcher at Leiden University Medical Center in the Netherlands. She and her colleagues presented a study earlier this year, at ENDO 2023, titled, “Metabolic and Neuroendocrine Adaptability Following One Night of Partial Sleep Restriction in Dutch Males.” Show notes are available at https://www.endocrine.org/podcast/enp80-metabolic-and-neuroendocrine-effects-of-short-sleep — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Today’s topic is type 1 diabetes. What are some of the biggest challenges facing us today when it comes to diagnosing and treating type 1 diabetes, and how can we meet those challenges? Host Aaron Lohr talks with Irl Hirsch, MD, from the UW Diabetes Institute at the University of Washington. Dr. Hirsch and Davida Kruger, NP, from Henry Ford Health in Detroit co-chaired the Endocrine Society’s type 1 diabetes fellows series. That program and this podcast episode were both made possible by unrestricted, educational grants from Abbott Diabetes Care Inc., CeQur Corp., Dexcom, Insulet, JDRF, Lilly USA LLC, MannKind Corp., Novo Nordisk, Prevention Bio, Vertex, and Tandem Diabetes Care. Show notes are available at https://www.endocrine.org/podcast/enp79-type-1-diabetes-update — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We know that illicit use of anabolic-androgenic steroids is dangerous, but cessation comes with its own challenges. Today we’re talking about a study presented at ENDO 2023 titled, “Self-Administration of Post-Cycle Therapy Is Associated With Increased Probability of Subsequent Normalisation of Reproductive Hormones Following Anabolic-Androgenic Steroid Cessation in Men.” Joining host Aaron Lohr to talk about it is one of the study authors, Channa Jayasena, MD, PhD, a specialist in reproductive endocrinology and a research team lead at Imperial College London. Show notes are available at https://www.endocrine.org/podcast/enp78-post-cycle-therapy-following-anabolic-androgenic-steroid-cessation — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We look at a study, presented at ENDO 2023, about the endocrine-disrupting chemicals known as phthalates, or plasticizers, and their effects on fetal and neonatal endocrine puberty. Host Aaron Lohr talks with Mary Bunnell from the University of Illinois Urbana-Champaign, co-author of the study, titled, “Prenatal Phthalate Exposure Alters the Pattern of Fetal and Neonatal Endocrine Puberty in a Sex-specific Manner.” Show notes are available at https://www.endocrine.org/podcast/enp77-phthalates-and-endocrine-puberty — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Today we look at a study from ENDO 2023 about COVID-19 exposure and weight gain in infants. Host Aaron Lohr talks with Mollie Ockene, a Clinical Research Coordinator at Massachusetts General Hospital and a co-author of the study, titled, “Accelerated Longitudinal Weight Gain Among Infants With

From ENDO 2023, host Aaron Lohr talks with Jayalakshmi Udayasankar, MD, from the Palo Alto Medical Foundation, about her team’s research presented at the meeting, titled, “Tingling Over Cheek: An Atypical Presentation of Invasive Fungal Sinusitis in an Ambulatory Patient With Type 2 Diabetes.” Show notes are available at https://www.endocrine.org/podcast/enp75-a-case-study-on-fungal-sinusitis-in-t2d — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In another dispatch from ENDO 2023, host Aaron Lohr talks with Max Petersen, MD, PhD, from Washington University in St. Louis, about his team’s research presented at the meeting. Their presentation was titled, “Cellular Insights Into Metabolically Healthy and Unhealthy Obesity.” Show notes are available at https://www.endocrine.org/podcast/enp74-healthy-and-unhealthy-obesity — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” Show notes are available at https://www.endocrine.org/podcast/enp73-a-robotic-teriparatide-pill-to-treat-osteoporosis — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In another interview from ENDO 2023, host Aaron Lohr talks with Silvana Duran Ortiz, Ph.D., a postdoctoral research fellow at Ohio University, about her team’s research presented at the meeting. Their presentation was titled, “Disruption of GHR in ‘Middle Aged’ Mice Enhances Insulin Sensitivity and Extends Male Lifespan.” Show notes are available at https://www.endocrine.org/podcast/enp72-ghr-insulin-and-life-span — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Host Aaron Lohr went to Chicago in June to interview researchers presenting at the Endocrine Society’s annual meeting, ENDO 2023. Here he talks with Julie Hens, PhD, from Yale University about her team’s research, titled “Protective Effects of Lactation on Maternal Metabolism.” After that interview, listen to a sneak peek of our other, members-only podcast,

Whether we like it or not, we’re all getting older. What do we know about how aging impacts our endocrine system? What don’t we know? That’s what we’re here to talk about today, as we look at the new scientific statement from the Endocrine Society titled, “Hormones and Aging: An Endocrine Society Scientific Statement.” Host Aaron Lohr talks with one of the statement’s authors, Anne Cappola, MD, a professor of medicine at the University of Pennsylvania and founding director of Penn Medical Communication Research Institute. Show notes are available at https://www.endocrine.org/podcast/enp70-hormones-and-aging — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we hear about biosimilar insulin: its safety, efficacy, what sets it apart from biologic insulin, and when it should be considered for use. Host Aaron Lohr talks with Irl Hirsch, MD, professor of medicine at the University of Washington Medicine Diabetes Institute. This episode is made possible through an unrestricted, educational grant from Viatris. Show notes are available at https://www.endocrine.org/podcast/enp69-biosimilar-insulin — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Recently the Endocrine Society published a new clinical practice guideline entitled, “Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.” What exactly is hypercalcemia of malignancy? What are its symptoms? How is it treated? And what do the guidelines recommend? To help answer these questions, host Aaron Lohr talks with Ghada El-Hajj Fuleihan, MD, MPH, professor of medicine at the American University in Beirut in Lebanon. She is the chair of the Society working group that developed this guideline. Show notes are available at https://www.endocrine.org/podcast/enp68-hypercalcemia-of-malignancy — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, host Aaron Lohr discusses screening, diagnosis, and current and emerging treatment options for the long-term management of growth hormone deficiency in pediatric and adult patients with Dr. Mark E. Molitch, MD, Professor Emeritus of Medicine, Northwestern University Feinberg School of Medicine. In addition, Dr. Molitch gives listeners a four-question quiz at the end. Remember to pause in between the question and answer! This episode is certified for up to 0.5 American Medical Association Physician’s Recognition Award (AMA PRA) Category 1 credits and American Board of Internal Medicine Maintenance of Certification (ABIM MOC) points. This episode is made possible by an unrestricted, educational grant from Novo Nordisk. Show notes are available at https://www.endocrine.org/podcast/enp67-growth-hormone-deficiency — for helpful links, including to the AMA PRA exam, or to hear more podcast episodes, visit https://www.endocrine.org/podcast

The Endocrine Society made news recently by launching a new, online-only, open-access journal called

In this episode, host Aaron Lohr looks back at the Endocrine Society’s Type 1 Diabetes Fellows Conference, which occurred last year, with two conference presenters talking about developmental challenges in type 1 diabetes, including psychological and social, across the lifespan. Our guests are Linda Siminerio, PhD, professor of medicine at University of Pittsburgh and executive director of the university’s Diabetes Institute, and Jill Weissberg-Benchell, PhD, professor of psychiatry and behavioral sciences at Northwestern University. Dr. Siminerio’s presentation was titled, “Identifying and Confronting Challenging Transitions.” Dr. Weissberg-Benchell’s presentation was titled, “Developmental Perspectives in the Psychosocial Aspects of Diabetes.” Thanks to the conference’s supporters who have made this episode possible through unrestricted, educational grants: Abbott Laboratories, Dexcom, Insulet, Lilly, Medtronic, Novo Nordisk, PreventionBio, and Tandem Diabetes Care. Editor’s note: this interview was recorded in 2022. Show notes are available at https://www.endocrine.org/podcast/enp65-type-1-diabetes-and-challenges-across-the-lifespan — for more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast